Active bleeding or pathologic condition that carries a high risk of bleeding (e.g., hereditary hemorrhagic telangiectasia). Patients with bleeding cutaneous lesions not actively requiring transfusions are eligible. Patients who have been uneventfully anti-coagulated with low molecular weight heparin are eligible
Active bleeding or pathologic condition that carries a high risk of bleeding. No bleeding diathesis.
Active uncontrolled bleeding
Active gastrointestinal bleeding
Active bleeding disorder in the past 6 months.
Patients with active bleeding or pathologic conditions that carry high risk of bleeding, such as known bleeding disorder, coagulopathy, or tumor involving major vessels
Active bleeding conditions
If receiving warfarin: INR ? 3.0 and no active bleeding (i.e., no bleeding within 14 days prior to first dose of study therapy).
History of bleeding disorders which would put a patient at risk for bleeding with anti-coagulation or patients with an increased risk of thromboembolic or hemorrhagic events (e.g., stroke).
Brain lesions or intracranial abnormalities at risk for bleeding, by history or radiologic imaging (e.g., active metastases).
Patients with uncontrolled coagulopathies who are at increased risk of bleeding.
Evidence of active bleeding or bleeding disorder
Significant risk for bleeding
Patients with history of intra-abdominal bleeding or retroperitoneal bleeding within the last 3 years are excluded
Subjects with untreated or incompletely treated varices with bleeding or high risk for bleeding; subjects treated with adequate endoscopic therapy (according to institutional standards) without any episodes of recurrent GI bleeding requiring transfusion or hospitalization for at least 6 months prior to enrollment are eligible
Active bleeding or a pathological condition that is associated with a high risk of bleeding (therapeutic anticoagulation is allowed)
Existing bleeding or condition associated with increased risk of bleeding
Active bleeding or pathologic condition that carries a high risk of bleeding (e.g., hereditary hemorrhagic telangiectasia)
Platelet count > 30,000 cells/mm^3 (30 x 10^9/L) without transfusion support; evidence of mucosal bleeding; a known bleeding episode within 3 months of screening; or a history of a bleeding disorder
No active bleeding
Active and significant bleeding
Active bleeding or pathologic condition that carries a high risk of bleeding (e.g. hereditary hemorrhagic telangiectasia); patients who have been uneventfully anti-coagulated with low molecular weight heparin are eligible
Active gastrointestinal bleeding
Patients with active bleeding or pathologic conditions that carry high risk of bleeding, such as a known bleeding disorder, coagulopathy, or tumor involving major vessels
Patients with a history of bleeding disorders or evidence of intracranial abnormalities which would put them at risk for bleeding with anti-coagulation (e.g., strokes, active metastases).
active bleeding or a high risk of bleeding contraindicating anticoagulant treatment;
Have active uncontrolled bleeding or a known bleeding disorder
Evidence of active mucosal or internal bleeding.
Evidence of active mucosal or internal bleeding.
Patients with active or prior digestive tract bleeding.
Known, increased risk of bleeding
Active bleeding disorder or other history of significant bleeding episodes within 30 days before study entry
Patients with active bleeding or pathologic conditions that carry high risk of bleeding, such as known bleeding disorder, coagulopathy, or tumor involving (in contact with, invading or encasing) major vessels
Active bleeding or a pathological condition that is associated with a high risk of bleeding (therapeutic anticoagulation is allowed)
Patients with bleeding disorders are ineligible due to lymph node removal possibly causing excessive bleeding; bleeding disorder will be defined by an INR level of > 2.0
No evidence of active bleeding
Patients with active bleeding or pathologic conditions that carry high risk of bleeding, such as known bleeding disorder, coagulopathy, or tumor involving major vessels
This criterion applies only to the patients enrolled before August 29, 2011 and those enrolled after this date electing to receive bevacizumab; patients with active bleeding or pathologic conditions that carry high risk of bleeding such as a known bleeding disorder, coagulopathy, or tumor involving major vessels
History of active bleeding within the last 3 months requiring transfusion
Patients with active bleeding or pathologic conditions that carry high risk of bleeding, such as known bleeding disorder, coagulopathy, or tumor involving major vessels
Subjects with untreated or incompletely treated varices with bleeding or high risk for bleeding.
Active bleeding or pathologic condition that carries a high risk of bleeding (e.g. hereditary hemorrhagic telangiectasia). Patients who have been uneventfully anti-coagulated with low molecular weight heparin are eligible.
Has active bleeding disorder or other history of significant bleeding episodes within 30 days of randomization.
Patients must not have active bleeding or a pathological condition that is associated with a high risk of bleeding
Patients with active bleeding or pathologic conditions that carry high risk of bleeding
Active bleeding or pathologic condition that carries a high risk of bleeding (e.g. hereditary hemorrhagic telangiectasia).
Active uncontrolled bleeding
Patients with active bleeding or pathologic conditions that carry high risk of bleeding, such as known bleeding disorder or coagulopathy.
Ongoing major bleeding,
Contraindications to prophylactic dose low molecular weight heparin (LMWH), including \r\n* Patients with recent gastrointestinal bleeding \r\n* History of heparin induce thrombocytopenia on LMWH\r\n* Subjects with previous severe hemorrhagic events on LMWH\r\n* Recent central nervous system bleed, intracranial or spinal lesion at high risk for bleeding\r\n* Active bleeding (major): more than 2 units transfused in 24 hours\r\n* Spinal anesthesia/lumbar puncture\r\n* Chronic, clinically significant measurable bleeding > 48 hours\r\n* Severe platelet dysfunction (uremia, medications, dysplastic hematopoiesis)\r\n* Recent major operation at high risk for bleeding\r\n* Underlying hemorrhagic coagulopathy\r\n* High risk for falls (head trauma)
Active bleeding disorders and high likelihood of bleeding or conditions or medications known to increase the risk of bleeding; patients with bleeding diathesis and subjects who are receiving anticoagulation treatment with INR > 2 are excluded
Patients with active bleeding or pathologic conditions that carry high risk of bleeding, such as known bleeding disorder, coagulopathy, or tumor involving major vessels
Patients with a history of significant tumor bleeding, or coagulation or bleeding disorders.
Patients with active bleeding or pathologic conditions that carry high risk of bleeding, such as known bleeding disorder, coagulopathy, or tumor involving major vessels
Evidence of mucosal or internal bleeding
Patients with untreated or incompletely treated varices with bleeding or high-risk for bleeding
Active uncontrolled bleeding
Uncontrolled severe bleeding tendency or active GI bleeding
Active bleeding or bleeding susceptibility
Active bleeding or a pathological condition that is associated with a high risk of bleeding
Patients with active bleeding or pathologic conditions that carry high risk of bleeding, such as known bleeding disorder, coagulopathy (in the absence of therapeutic anticoagulation), or tumor involving major vessels.
For subjects with known or suspected cirrhosis, esophagogastroduodenoscopy ) within 12 months of signing the informed consent form, showing no evidence of untreated varices or stigmata of active bleeding (such as active ulcer, visible vessel, or blood) is required. Subjects with history of upper GI bleeding must have an EGD of 3 months or less prior to signing the consent form confirming adequate prior endoscopic therapy (eg, no evidence of any untreated varices, recent or active bleeding, stigmata suggesting high risk for bleeding, active ulcer). Subjects with history/suspected esophageal varices must be on optimal medical management (eg, proton pump inhibitor and non-selective beta-blocker) per local institutional policy.
Subjects with current/a history of bleeding disorder or coagulopathy or who are at particularly high risk for bleeding complications.
Ongoing risk of bleeding.
Active bleeding disorders or clinical signs of bleeding (Grade ?2).
Active bleeding that requires hospitalization during the screening period
Recent hemoptysis >2.5 mL or serious bleeding from another site, known bleeding disorder or coagulopathy or therapeutic anti-coagulation
Active bleeding or high risk for bleeding contraindicating treatment with LMWH or edoxaban;
History of bleeding diasthesis
Ongoing major bleeding,
Active bleeding; pathological condition that carries a high risk of bleeding; risk of pseudoaneurysm of the internal carotid artery and carotid blowout syndrome.
Endometrial bleeding
Active bleeding
Patients with an underlying diagnosis or disease state associated with an increased risk of bleeding.
Target bleeding site has moderate bleeding according to the Investigator's judgment.
The target bleeding site has a mild or severe bleeding.
If receiving warfarin: INR ? 3.0 (and no active bleeding, [i.e., no bleeding within 14 days prior to first dose of study therapy])
No active bleeding
No active bleeding
Active bleeding or high risk of bleeding
Active gastrointestinal bleeding
Active bleeding
Patients with active bleeding or pathologic conditions that carry high risk of bleeding, such as known bleeding disorder, coagulopathy, or tumor involving major vessels by imaging, regardless of whether any chance of requiring vascular reconstruction
Active bleeding
Active bleeding that requires hospitalization during the screening period
Evidence of active bleeding or pathologic conditions that carry high risk of bleeding such as known bleeding disorders, coagulopathy or tumor involving major vessels
No central lung metastases with excessive active bleeding
No active bleeding or pathological condition that carries a high risk of bleeding (e.g., tumor involving major vessels or known varices) within 14 days prior to registration
No clinical signs active of bleeding
Patients with overt bleeding
Active bleeding or high risk of bleeding in the opinion of the investigator
Active bleeding (grade 2 or higher) at the time of enrollment
Active bleeding
Participants with untreated or incompletely treated varices with bleeding or high-risk for bleeding
Active or serious bleeding within two weeks of enrollment
Active major bleeding
Active bleeding or high risk for bleeding (e.g. known acute gastrointestinal ulcer)
Patients on anticoagulation or with bleeding disorders should be evaluated by a physician for risk/benefit of bleeding disorders with intramuscular injections prior to study enrollment; patients determined to be at high risk for bleeding with intramuscular injections will be excluded
Active bleeding condition (not limited to: thrombocytopenia, hemophilias, potential bleeding lesions, recent trauma or surgery, recent stroke, confirmed intracranial or intraspinal bleeding)
Bleeding diathesis, hemorrhagic lesions, active bleeding, and other conditions with a high risk for bleeding
Evidence of active mucosal or internal bleeding
active bleeding or at high risk of bleeding
Active vaginal bleeding requiring packing and emergent radiation therapy
Any condition resulting in increased risk of bleeding at biopsy.
No active bleeding
No active bleeding in the post-operative period
Active bleeding or high risk of bleeding
Bleeding and Thrombosis:
If active bleeding requiring acute surgical intervention, not eligible
Active bleeding or pathologic condition that carries a high risk of bleeding
